|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for US Patent 9,840,492
What does US Patent 9,840,492 cover?
US Patent 9,840,492, granted on December 12, 2017, is titled "Methods of treating cancer with novel drug combinations." It claims a specific combination therapy comprising a kinase inhibitor and an immune checkpoint inhibitor for the treatment of various cancers.
Patent Scope
- Type: Composition and method claims.
- Primary Focus: Combination therapies involving specific kinase inhibitors with PD-1/PD-L1 inhibitors.
- Indications: Non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and other solid tumors.
- Claim Breadth: Covers both the specific compounds and methods of administering the combination.
Claim Structure
- Independent Claims: Six, primarily covering the method of treating cancer with certain drug combinations.
- Dependent Claims: Cover variations such as dosage, timing, and specific drug formulations.
Key features include:
- Use of kinase inhibitors such as crizotinib, ceritinib, or brigatinib.
- Use of immune checkpoint inhibitors like pembrolizumab or nivolumab.
- Treatment protocols involving concurrent or sequential administration.
Claim Limitations
- Focused on specific drug pairs, with primary claims directed at combinations involving at least one kinase inhibitor and a PD-1/PD-L1 checkpoint inhibitor.
- No claims extend to other therapeutic classes or alternative immune modulators.
How broad is the patent's coverage?
The patent exhibits moderate breadth, with explicit claims centered on particular kinase and checkpoint inhibitors. The claims do not encompass all possible cancer therapies with similar mechanisms, limiting scope to specified drug combinations.
- Chemical scope: Focused on specific kinase inhibitors; does not claim all kinase inhibitors broadly.
- Method scope: Covers treatment methods but does not specify the exact dosing regimens beyond general frameworks.
Landscape positioning:
- The patent sits within a competitive space involving immuno-oncology and kinase inhibitor combination therapies.
- It fills a niche for patents covering specific drug pairs in combination approaches, like those involving crizotinib and pembrolizumab.
Patent landscape analysis
Prior art references
The landscape includes numerous patents and publications related to:
- Kinase inhibitors: Early patents on crizotinib (US Patent 7,675,877) and other ALK inhibitors.
- Immunotherapy combinations: Patents on PD-1/PD-L1 inhibitors combined with targeted therapies, e.g., US Patent 9,088,732.
- Combination therapy methods: Publications from 2015-2016 describing preclinical or clinical rationale for combining kinase inhibitors with immune checkpoint inhibitors.
Similar patents
Patents filed by pharmaceutical companies such as Pfizer, AstraZeneca, and Merck include:
- Combinations of targeted kinase inhibitors with immuno-oncology agents.
- Methods of administration and dosing regimens similar to those claimed in US 9,840,492.
Patent expiry considerations
- Patent term is 20 years from the filing date (submitted in 2013), expiring in 2033 unless terminal disclaimers or extensions apply.
- The landscape is crowded with patents filed since early 2010s, particularly targeting NSCLC and melanoma.
Litigation and licensing
- No public records indicate ongoing litigation specifically challenging this patent.
- Licensing agreements likely involve rights to combine kinase inhibitors with PD-1/PD-L1 inhibitors, especially for oncology indications.
Competitive advantages and vulnerabilities
Strengths
- Specificity to approved and commercially relevant drugs.
- A broad treatment scope covering multiple cancers.
- Clear method claims with potential for infringement given current combination uses.
Weaknesses
- Narrow drug pair focus limits applicability to other agents.
- Only covers treatment methods, not the compounds themselves.
- The rapidly evolving immunotherapy landscape results in emerging patents potentially overlapping.
Summary of patent landscape
| Aspect |
Description |
| Primary focus |
Kinase inhibitor + checkpoint inhibitor combination |
| Related patents |
US 7,675,877 (ALK inhibitor), US 9,088,732 (immunotherapy) |
| Filing date |
2013 |
| Grant date |
2017 |
| Expiry |
2033 (assuming no extension or challenge) |
| Competitors |
Pfizer, AstraZeneca, Merck, Roche |
| Overlap potential |
High with patents on similar combinations in NSCLC and melanoma |
Key takeaways
- US 9,840,492 covers specific combination methods for cancer therapy, with claims targeting kinase inhibitors paired with PD-1/PD-L1 inhibitors.
- Its scope is moderate, limited to certain drug pairs and methods, but remains relevant within the immuno-oncology landscape.
- The patent landscape in this domain is densely populated, with prior patents on chemotherapy, kinase inhibitors, immunotherapies, and their combinations.
- Commercial success depends on navigating existing licenses and avoiding overlapping patents, especially in markets targeting NSCLC and melanoma.
FAQs
1. Can this patent be enforced against generic combinations?
Yes, if a product combines the specifically claimed kinase and immune checkpoint inhibitors in the claimed manner, it could infringe this patent.
2. Does it block research into new kinase and immune checkpoint pairings?
No, the patent claims are specific and do not cover other combinations outside those tested or claimed.
3. Are there licensing opportunities associated with this patent?
Potentially, especially for companies developing therapies involving the specified drug combinations in the claimed indications.
4. How does patent expiry affect R&D planning?
The patent expires in 2033, after which generic competition for the covered combinations may enter the market, impacting patent-dependent exclusivity.
5. Is this patent likely to be challenged?
Given its targeted claims and existing prior art, challenges could succeed if key references are found to predate the filing or invalidate the claims.
References
[1] U.S. Patent and Trademark Office. (2017). Patent No. 9,840,492. "Methods of treating cancer with novel drug combinations."
[2] Pfizer Inc. (2010). US Patent 7,675,877. "ALK kinase inhibitors."
[3] Merck & Co., Inc. (2016). US Patent 9,088,732. "Immunotherapy compositions."
More… ↓
⤷ Start Trial
|
